Clinical Trial Update: A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study of PGN-EDO51 or placebo for Duchenne muscular dystrophy amenable to exon 51 skipping has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PGN-EDO51

Snippet

Sponsor: PepGen Inc | Conditions: Duchenne Muscular Dystrophy (DMD) | Phase 2 | Status: WITHDRAWN